Real-world evidence (RWE) solutions market expected to be worth over $5 billion by 2027

An article we posted earlier this year stated that the RWE market was set to grow to being worth over $1 billion by 2023. However, now new research shows the market will grow massively in the 4 years following to being worth over $5 billion by 2027. It’s very possible that real-world evidence studies have pushed towards the forefront of research due to the ongoing COVID-19 pandemic.

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: NOV2020BR001